Dalteparin sodium
Fragmin (dalteparin sodium) is an oligosaccharide pharmaceutical. Dalteparin sodium was first approved as Fragmin on 1994-12-22. It is used to treat myocardial infarction, postoperative complications, pulmonary embolism, thromboembolism, and thrombophlebitis amongst others in the USA. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Clinical
Clinical Trials
1554 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombosis | D013927 | — | — | 9 | 30 | 50 | 45 | 92 | 219 |
| Thromboembolism | D013923 | HP_0001907 | — | 7 | 21 | 65 | 37 | 79 | 203 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 7 | 18 | 48 | 27 | 66 | 161 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 5 | 19 | 34 | 28 | 50 | 132 |
| Covid-19 | D000086382 | — | — | 6 | 30 | 30 | 14 | 36 | 102 |
| Embolism | D004617 | — | — | 6 | 4 | 24 | 26 | 27 | 86 |
| Pulmonary embolism | D011655 | HP_0002204 | I26 | 7 | 5 | 23 | 26 | 25 | 85 |
| Infarction | D007238 | EFO_0009463 | — | — | 3 | 16 | 27 | 24 | 70 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 3 | 17 | 26 | 23 | 69 |
| Syndrome | D013577 | — | — | 7 | 17 | 11 | 11 | 15 | 57 |
Show 176 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Septic shock | D012772 | — | A48.3 | 1 | 3 | 2 | — | 14 | 20 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 2 | 4 | — | 12 | 18 |
| Healthy volunteers/patients | — | — | — | 14 | 1 | 1 | — | 3 | 18 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 5 | 3 | — | 4 | 14 |
| Plasma cell neoplasms | D054219 | — | — | 3 | 5 | 3 | — | 4 | 14 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | 2 | 7 | 3 | — | 5 | 14 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 3 | 3 | 2 | — | 3 | 11 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 1 | — | 8 | 9 |
| Coagulation protein disorders | D020147 | — | — | 1 | — | 1 | — | 5 | 7 |
| Intracranial thrombosis | D020767 | — | — | — | 2 | 3 | — | 2 | 6 |
Show 104 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | 4 | — | — | 1 | 6 |
| Coronary stenosis | D023921 | EFO_1000882 | — | — | 1 | — | — | 4 | 5 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 1 | — | — | 2 | 4 |
| Carotid artery diseases | D002340 | EFO_0003781 | — | — | 1 | — | — | 3 | 4 |
| Cytokine release syndrome | D000080424 | — | D89.83 | — | 1 | — | — | 3 | 4 |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | 1 | — | — | 3 | 4 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 1 | — | — | 2 | 3 |
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | — | 1 | — | — | 2 | 3 |
| Somatoform disorders | D013001 | — | F45 | — | 3 | — | — | — | 3 |
| Hemolysis | D006461 | — | — | — | 1 | — | — | 2 | 3 |
Show 56 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blood platelet disorders | D001791 | — | — | 1 | — | — | — | 3 | 4 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | — | — | — | 2 | 3 |
| Blood pressure | D001794 | EFO_0004325 | — | 2 | — | — | — | — | 2 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 1 | — | — | — | 1 | 2 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | 1 | — | — | — | 1 | 2 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | 1 | 2 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | — | — | — | — | 1 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | — | — | — | — | 1 |
| Cesarean section | D002585 | — | — | 1 | — | — | — | — | 1 |
| Heart rate | D006339 | EFO_0004326 | — | 1 | — | — | — | — | 1 |
Show 20 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 5 | 5 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 4 | 4 |
| Carotid stenosis | D016893 | — | — | — | — | — | — | 4 | 4 |
| Chest pain | D002637 | HP_0100749 | R07.9 | — | — | — | — | 4 | 4 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | — | 4 | 4 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 4 | 4 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | — | — | 4 | 4 |
| Post-acute covid-19 syndrome | D000094024 | — | — | — | — | — | — | 4 | 4 |
| Blood coagulation | D001777 | GO_0007596 | — | — | — | — | — | 3 | 3 |
| Thoracic aortic aneurysm | D017545 | EFO_0004282 | — | — | — | — | — | 3 | 3 |
Show 225 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dalteparin sodium |
| INN | dalteparin sodium |
| Description | Dalteparin is a low molecular weight heparin. It is marketed as Fragmin. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of a stroke or heart attack. Dalteparin acts by potentiating the activity of antithrombin III, inhibiting formation of both Factor Xa and thrombin. It is normally administered by self-injection.
|
| Classification | Oligosaccharide |
| Drug class | heparin derivatives and low molecular weight (or depolymerized) heparins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | 67109 |
| ChEMBL ID | CHEMBL1201460 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06779 |
| UNII ID | 12M44VTJ7B (ChemIDplus, GSRS) |
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Fragmin – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dalteparin sodium
+
Dalteparin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,334 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fragmin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,026 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use